Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (Nasdaq: TLSA) announced on Dec 15, 2025 that it has withdrawn its proposed public offering of common shares. The company said the withdrawal was made due to market conditions. The release also states that it does not constitute an offer to sell or a solicitation to buy securities in any jurisdiction prior to required registration or qualification.
Tiziana Life Sciences (Nasdaq: TLSA) announced on Dec 12, 2025 that enrolment has begun in its Phase 2 randomized, placebo-controlled early Alzheimer’s trial and the company expects to dose the first patient next week. The study will test intranasal foralumab as monotherapy and combined with FDA-approved anti-amyloid therapies lecanemab or donanemab.
Baseline cognitive testing, fluid biomarkers and TSPO-PET imaging were completed in initial participants; new TSPO-PET evidence showed persistent, widespread microglial activation in an Alzheimer’s patient despite treatment with lecanemab, supporting the trial rationale to target residual neuroinflammation.
Tiziana Life Sciences (Nasdaq: TLSA) intends to spin out its fully human anti-IL-6 receptor program TZLS-501 into a separately listed, immunology-focused company and will distribute shares in specie to Tiziana shareholders at a record date to be announced. TZLS-501 targets both membrane-bound and soluble IL-6R and was advanced for development due to heightened industry interest in IL-6 therapeutics, noted alongside Novartis' $1.4 billion acquisition of Tourmaline Bio.
The transaction requires shareholder approval and meeting listing criteria; TZLS-501 remains a Tiziana asset until approvals are obtained.
Tiziana Life Sciences (Nasdaq: TLSA) announced on November 25, 2025 that its Phase 2 trial of intranasal foralumab in amyotrophic lateral sclerosis (ALS) was accepted into the Healey ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham.
The study, supported by a competitive grant from the ALS Association, will be led by Principal Investigators Suma Babu and James Berry and will enroll at multiple rapid-enrolling U.S. centers within the NEALS consortium. Successful investigational agents in MyMatch may advance to the HEALEY ALS Platform Trial or to standalone Phase 3 trials. The trial will use nasal immunology, blood and spinal fluid markers, cellular assays, and advanced brain imaging to evaluate foralumab’s effect on regulatory T cells and CNS inflammation.
Tiziana Life Sciences (Nasdaq: TLSA) said its senior leadership will present a corporate overview at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025. The presentation is scheduled for 12:30 p.m.–12:55 p.m. GMT and will run 25 minutes.
CEO Ivor Elrifi and COO/CFO Keeren Shah will discuss the company’s pipeline and recent clinical milestones, including an update on lead candidate intranasal foralumab, a fully human anti‑CD3 monoclonal antibody in clinical development for neurodegenerative diseases such as non‑active SPMS, Alzheimer’s disease, MSA, and ALS. Management will be available for one‑on‑one meetings via the conference portal or investor relations.
Tiziana Life Sciences (Nasdaq: TLSA) will present at BIO-Europe 2025 in Vienna on November 3–5, 2025, where management led by CEO Ivor Elrifi will hold one-on-one partnering meetings with biopharma executives and investors.
The presentation will highlight Tiziana’s intranasal foralumab, a fully human anti-CD3 monoclonal antibody in clinical development, and the company’s nasal delivery platform aimed at improving efficacy, safety, and tolerability versus IV dosing. Ongoing programs include Phase 2 trials in non-active secondary progressive MS (na-SPMS) and Multiple System Atrophy (MSA); Phase 2 studies in early Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) are planned to commence.
BIO-Europe 2025 is expected to attract over 5,700 delegates from 60+ countries, offering partnering opportunities to advance Tiziana’s immunomodulation pipeline.
Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company focused on immunomodulation therapies, has been invited to the J.P. Morgan Asset Management Life Science Innovation Forum (LSIF) 2025 in Riyadh, Saudi Arabia. The event will take place on October 1-2, 2025 at the King Saud bin Abdulaziz University for Health Sciences Conference Center.
The forum aims to accelerate life science research commercialization and strengthen the biotechnology value chain in Saudi Arabia. The company will have the opportunity to present its clinical pipeline, including its lead candidate intranasal foralumab, a fully human anti-CD3 monoclonal antibody, to potential investors and strategic partners.
Tiziana Life Sciences (NASDAQ:TLSA) announced plans to advance TZLS-501, its fully human anti-IL-6 receptor monoclonal antibody. The decision follows Novartis' $1.4 billion acquisition of Tourmaline Bio, highlighting increased industry interest in IL-6 pathway therapeutics.
TZLS-501's dual mechanism of action targets both membrane-bound and soluble forms of IL-6R, blocking IL-6R signaling and reducing inflammatory cytokines. The company will pursue non-dilutive funding for TZLS-501's development while maintaining focus on its lead program, intranasal foralumab. The therapeutic shows potential for treating multiple conditions including rheumatoid arthritis, ARDS, pulmonary fibrosis, lupus, and various cancers.
Tiziana Life Sciences (NASDAQ:TLSA) announced its upcoming poster presentation at the 41st ECTRIMS Congress in Barcelona, Spain, from September 24-26, 2025. The presentation will focus on the Phase 2a clinical trial design for nasal foralumab, the first fully human anti-CD3 monoclonal antibody designed for intranasal delivery.
The study targets non-active secondary progressive multiple sclerosis patients, representing a novel approach to immune system modulation. The presentation, titled "Study Design of a Phase 2a Double-Blind Placebo-Controlled Trial of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis," will be showcased at ECTRIMS, the world's largest annual international conference for MS research.
Tiziana Life Sciences (NASDAQ:TLSA) has received a significant research grant from the U.S. Department of Defense to study intranasal anti-CD3 therapy for traumatic spinal cord injury (SCI). The company will conduct a three-year study focused on acute SCI treatment, complemented by a two-year Stepping Strong Breakthrough Award for chronic phase research.
The research targets a substantial market with 300,000 Americans living with permanent disability and 17,000 new cases annually. Preclinical results at Brigham and Women's Hospital have shown promising motor outcome improvements. The non-invasive intranasal delivery method aims to rebalance the immune system and reduce inflammation in injured spinal cords.